Combo yields results

Article

Maxim Pharmaceuticals has announced that advanced metastatic melanoma patients treated with a combination of Ceplene and Interleukin-2 (IL-2) showed improved survival rates in a phase 3 trial, according to a Business Wire report.

Related Videos
Related Content

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.